The Wegovy pill versus Foundayo fight now has a second front, and it is not about weight loss. It is about counting. Two drugmakers are watching the same rapidly developing U.S. market for oral obesity medicines and presenting sharply different pictures of who is winning new patients.
On November 4, Novo Nordisk told investors that the Wegovy pill held approximately 80% of new-to-brand prescriptions for oral obesity medicines. Six days earlier, Eli Lilly told investors that about four in ten patients starting an oral obesity medicine were choosing Foundayo, its once-daily orforglipron tablet.
If both figures described the same two-product market, used identical definitions and covered the same period, they would not fit together. They do not. The measurements draw on different mixes of data, and some of the largest digital routes to obtaining prescriptions are imperfectly represented in conventional reporting.
The question is not whether Novo is leading the visible prescription race. It is. The question is how much the published margin tells us about all the people actually starting treatment.
Two Companies, Two Different Measures of New Starts
Novo’s third-quarter investor presentation is unusually helpful because its footnote explains part of the calculation. Page 9 says its weekly Wegovy pill estimates combine internal self-pay information with IQVIA Xponent, while new-to-brand figures for orforglipron and other treatments are based on IQVIA Xponent. The source cutoff printed on that slide is October 2, 2026.
Lilly’s Q3 presentation tells a different story. Its Foundayo launch slide charts a four-week rolling average of new-to-brand prescriptions and new-to-brand market share from April through September, with an accompanying statement that Foundayo’s share of new patient starts exited the quarter at approximately 40%.
Those are both company-reported measures of recent demand. Neither is a complete, independently reconciled census of patients across every cash-pay, pharmacy, subscription and telehealth channel. Even where the concepts overlap, different data collection, definitions and reporting cutoffs can produce different answers.
A further distinction matters: a new-to-brand prescription is not automatically a patient who has never used any GLP-1 medicine. Someone moving from an injection to a pill may be new to a brand without being new to the drug class. The words “new prescription,” “new patient” and “new to treatment” should not be swapped casually.
The Weekly Prescription Numbers Still Favor Novo
In the conventional prescription data, the gap is considerably easier to see. Fierce Pharma’s October 30 IQVIA-based tracker update reported 63,110 total weekly prescriptions for Foundayo and approximately 183,000 for the Wegovy pill. Those visible counts put Novo at roughly three times Lilly’s volume for the period reported.
Jefferies estimated in October that Lilly held a little more than one-quarter of the observed oral GLP-1 prescription market, against nearly three-quarters for Novo. That is an analyst’s share estimate based on available prescription data, not a verified all-channel count.
Launch timing helps explain some of the gap. The Wegovy pill became available in January 2026; Foundayo followed in April. Total prescriptions include refills from people who started earlier. A medicine with a three-month head start can therefore dominate weekly filled prescriptions while a newer competitor gains a larger portion of recent starts.
Revenue offers another view, but not a substitute for patient counts. Lilly’s official Q3 results recorded $184 million in worldwide Foundayo revenue, compared with approximately $98 million in Q2. Novo reported DKK 5.394 billion in Q3 Wegovy pill sales across its launched markets. The figures have different launch histories and currency bases and cannot, by themselves, establish patient share.
Lilly has argued that underlying U.S. Foundayo demand more than tripled when the impact of initial Q2 distribution inventory is removed. That makes the growth trend meaningful without changing who leads the currently visible volume scoreboard.
The market leader in reported prescriptions is not necessarily the winner of every measure of new-patient growth.
Why Telehealth Changes the Scoreboard
Novo’s criticism of the usual data sources goes directly to distribution. On the November 4 earnings call, chief executive Mike Doustdar said IQVIA captured about 90% to 95% of Lilly prescriptions but only approximately 65% of Novo’s, a discrepancy he attributed to partners whose transactions were not fully reflected in the service’s reports.
Those capture rates are Novo’s characterization, not figures independently audited by IQVIA in the material reviewed for this article. Still, the broader issue is real: retail pharmacies, direct-to-consumer programs, fulfillment partners and telehealth services do not all contribute identical records to every commercial prescription database.
There is a counterweight to the idea that this is only a Novo problem. During Foundayo’s April launch, Lilly said more than a dozen major telehealth platforms accounted for about 35% of early Foundayo volume. That figure does not tell us what fraction was missing from IQVIA, and it cannot be applied to the entire obesity-drug market.
The channel map is also changing in real time. On November 6, Reuters reported that Lilly had reached an agreement allowing Hims & Hers customers to buy Foundayo and Zepbound directly through the platform. Novo’s medicines were already offered there. That new arrangement does not settle the old prescription dispute, but it makes clear why an analysis of distribution channels can become outdated almost overnight.
In a market increasingly accessed through websites and apps, a vendor’s market-share figure is partly a measure of which transactions its reporting network can see.
Why the Missing-Prescription Calculation Does Not Prove 80 Percent
It is tempting to take those late-October IQVIA totals and divide them by Novo’s estimated capture rates. Using approximately 183,000 visible Wegovy pill prescriptions at 65% capture implies roughly 282,000 prescriptions. Using 63,110 visible Foundayo prescriptions at 90% capture implies roughly 70,000. On those assumptions alone, Novo would account for about 80% of the two products’ adjusted weekly prescription volume.
But that is an illustration, not an independent finding. The capture assumptions come from Novo; the published weekly counts are estimates; the percentages may differ across partners and change over time; and applying a company-wide capture factor to a particular weekly total has not been independently validated.
Most importantly, an estimated share of total weekly prescriptions is not the same as a share of new patient starts. Reaching a similar 80% number by two different calculations does not confirm Novo’s new-to-brand claim. It only shows how sensitive the resulting estimate is to the assumed missing data.
The public would need aligned dates, common patient definitions and complete channel-level totals before treating the rival companies’ percentages as directly comparable.
Why the Dispute Matters Beyond Investor Presentations
This is not merely investor-relations sparring. Analysts use prescription volumes to forecast drug revenue. If a data service observes some distribution models more completely than others, those assumptions can affect sales projections and the market’s interpretation of launch momentum.
Health plans and employers also need reliable utilization measures when forecasting demand. The federal Medicare GLP-1 Bridge adds a further reporting distinction. According to the Centers for Medicare & Medicaid Services, the temporary program runs outside the normal Part D benefit and payment flow, with a central processor handling claims in 2026. Those claims should not automatically be assumed to appear in every ordinary Part D or commercial dataset.
Novo executives referred to approximately 60,000 weekly prescriptions through the Bridge during the Q3 call, according to Fierce Pharma, but the reported number concerns Bridge activity and should not be assigned wholly to Wegovy pills.
The patient-level question is different again. Novo estimates that approximately 80% of people starting its pill are new to GLP-1 obesity medicines. If that estimate holds across the broader market, pills may be bringing additional people into treatment instead of simply replacing injections. It does not, by itself, establish how much of the class’s expansion belongs to either company.
These are separate questions: who fills the most prescriptions, who attracts recent brand starts, who reaches people new to treatment, and how much actual treatment persists over time. One market-share percentage cannot answer all four.
The real problem is not that the companies count differently. It is that the public cannot yet reconcile their counts.
The Next Scoreboard Update
The cleanest comparison would show total U.S. patients using each pill, new patient starts, refills, source channels and the share of each category missing from outside data vendors, all for the same reporting periods. Neither company has published a complete table of that kind.
The near-term checks are straightforward. Weekly IQVIA reports in November and December can show whether the visible volume gap narrows. Hims & Hers is scheduled to announce its third-quarter results on November 9, although that disclosure may not break out branded obesity pill prescriptions. The companies’ fourth-quarter results will be another opportunity to separate actual demand from initial inventory effects.
For clinical context rather than market share, Grey Pepper has separately examined indirect comparisons involving Foundayo and oral semaglutide. The financial performance behind the two oral launches is documented in their Q3 company earnings materials linked below.
For now, the most defensible answer to who is winning the U.S. oral obesity medicine race is narrow. Novo leads by a wide margin in reported total prescriptions and has the larger established pill business. Lilly’s new-start share is rising, according to its own figures. The precise all-channel gap between the two remains unresolved.
The next question is not which company can produce the bigger percentage. It is which company can show exactly who was counted.
Sources and Further Reading
- Novo Nordisk, Q3 2026 Investor Presentation, slide 9: oral obesity new-to-brand share and data-source footnotes
- Eli Lilly, Q3 2026 Earnings Call Presentation, slide 12: Foundayo new-start share
- Eli Lilly, Q3 2026 Official Financial Results, October 29, 2026
- Fierce Pharma, Oral GLP-1 Prescription Tracker, updated October 30, 2026
- BioSpace, Novo and Lilly Battle Over Oral GLP-1 Data, November 4, 2026
- Fierce Pharma, Novo Reports Q3 Wegovy Pill Growth and Medicare Bridge Activity, November 4, 2026
- CMS, Medicare GLP-1 Bridge: Program and Claims Structure
- Reuters, Lilly to Sell Obesity Drugs Directly Through Hims & Hers, November 6, 2026
- Hims & Hers Investor Relations, Q3 Earnings Scheduled for November 9, 2026
